Company Profile
Codexis Stock Price, News & Catalysts
- Ticker:
- CDXS
- Exchange:
- NASDAQ
- Sector:
- Biopharma
- Location:
- United States
Stock performance
1.66 USD (-0.60%)
Close
Last updated: August 24, 2026
245M USD
Market cap
Why the stock is moving
As of Aug 24, 2026, CDXS closed down 0.60% at $1.66. No new same-company headline was identified in the current news window.
Company overview
Business overview
Codexis is an enzyme-engineering company that serves pharma manufacturing, therapeutics, and bioprocessing needs. Its business is built around using protein engineering to solve industrial and healthcare problems.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Codexis sits in life-sciences tools and biotech infrastructure.
Business Model Characteristics
The company depends on platform adoption, customer relationships, and the monetization of engineered enzymes across markets.
Position Within the Biotechnology Landscape
Codexis is a biotech-enabling platform name rather than a drug developer.
Future catalysts
- Codexis’s catalysts are enzyme-engineering partnerships, next-gen biocatalyst demand, and any update that shows the platform is still winning in pharma manufacturing and sequencing workflows. Investors will care about whether recurring platform revenue keeps proving the model works.
Recent news
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.
Frequently Asked Questions
What is the current stock price of Codexis (CDXS)?
Codexis (CDXS) most recently closed at 1.66 USD, a -0.60% move versus the previous session.
What is the market cap of Codexis (CDXS)?
Codexis currently has a market capitalization of 245M USD on BioPharmSignal.
What does Codexis do?
Codexis is an enzyme-engineering company that serves pharma manufacturing, therapeutics, and bioprocessing needs. Its business is built around using protein engineering to solve industrial and healthcare problems.
On which exchange is CDXS stock listed?
Codexis (CDXS) is associated with NASDAQ, United States, Biopharma.
What is Codexis?
Codexis’s catalysts are enzyme-engineering partnerships, next-gen biocatalyst demand, and any update that shows the platform is still winning in pharma manufacturing and sequencing workflows.
Which conditions is Codexis targeting with Codexis?
Codexis’s catalysts are enzyme-engineering partnerships, next-gen biocatalyst demand, and any update that shows the platform is still winning in pharma manufacturing and sequencing workflows.
How does Codexis describe recent progress with Codexis?
Codexis’s catalysts are enzyme-engineering partnerships, next-gen biocatalyst demand, and any update that shows the platform is still winning in pharma manufacturing and sequencing workflows.
What is Investors?
Investors will care about whether recurring platform revenue keeps proving the model works.